Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

FDA clears SSRI for depression

July 22, 1998

Preclinical results point to anxiolytic efficacy for Yoshitomi benzodiazepine

July 22, 1998

Analgesic effects of dosulepin in patients with cancer-related pain

July 22, 1998

Icos begins phase II multiple-dose trial in multiple sclerosis patients

July 22, 1998

Spotlight on sigma-receptors as a target for intervention in CNS disorders

July 22, 1998

Benzodiazepine omega3 receptor ligands with anxiolytic, anticonvulsant and antiarthritic effects

July 22, 1998

New indication explored for established anticonvulsant

July 21, 1998

EEG analysis reveals the atypical antipsychotic profile of OPC-14597

July 21, 1998

SIB-1553A goes head-to-head with established cognition-enhancing drugs

July 21, 1998

Hypnotic effects of the benzodiazepine receptor ligand SX-3228 in rats

July 21, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...